Century Therapeutics Q3 net loss $30.7M; cash $395.3M; CNTY-101 trial imminent

Century Therapeutics, Inc.

2022-Q3 EPS reported -$1.72 revenue$4,678,000

Net loss $30.7M for Q3 2022 vs $26.0M in Q3 2021; R&D expenses rose to $25.9M.
Cash, cash equivalents, and investments totaled $395.3M at Sep 30, 2022; runway into 2025.
Full-year 2022 GAAP operating expense guidance lowered to $140M-$145M (incl. $10-$15M stock comp).
Phase 1 ELiPSE-1 trial of CNTY-101 in B-cell malignancies to begin imminently after FDA clearance.
Appointed Daphne Quimi and Timothy Walbert to Board; SITC data and R&D Day on Nov 11.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Century Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue Collaboration revenue was $2.2 million, net income Net loss was $30.7 million. Guidance lowered.

Period: the third quarter ended September 30, 2022
Revenue: Collaboration revenue was $2.2 million
Net income: Net loss was $30.7 million
Guidance: lowered
Result: reported results

Exact text from the filing

of $118.5 million) compared to net cash used in operations of $64.7 million for the nine months ended September 30, 2021. ● Collaboration Revenue: Collaboration revenue was $2.2 million for the three months ended September 30, 2022, generated through the Company’s collaboration, option and license agreement with BMS. ● Research and Development (R&D) expenses

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-116808

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.